FIRST LINE TREATMENT BY THE RIBVD REGIMEN ELICITS HIGH CLINICAL AND MOLECULAR RESPONSE RATES AND PROLONGED SURVIVAL IN ELDERLY MCL PATIENTS; FINAL RESULTS OF a LYSA GROUP TRIAL
| Autor: | Jehan Dupuis, Selim Corm, Remy Gressin, Roch Houot, Christiane Mounier, Sylvain Carras, Caroline Dartigeas, M. Macro, Ghandi Damaj, Nicolas Daguindau, Mary Callanan, Jean-Michel Pignon, Anne-Sophie Moreau, S. Le Gouill, Adrien Tempescul, P. Feugier, Fabrice Jardin, Guillaume Cartron, Luc Mathieu Fornecker, I. Ysebaert, A. Bannos, Lionel Karlin, J. Fleury, Anna Schmitt, Cecile Chabrot |
|---|---|
| Rok vydání: | 2017 |
| Předmět: |
Cancer Research
Pediatrics medicine.medical_specialty Group trial business.industry Hematology General Medicine First line treatment 03 medical and health sciences Regimen 0302 clinical medicine Oncology 030220 oncology & carcinogenesis Molecular Response Internal medicine medicine business 030215 immunology |
| Zdroj: | Hematological Oncology. 35:141-142 |
| ISSN: | 0278-0232 |
| DOI: | 10.1002/hon.2437_131 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text